More M&A For Astellas As It Pursues New Mid-Term Goals?
This article was originally published in PharmAsia News
Astellas's new mid-term business plan envisages mid-single-digit sales growth for the company over the next two years, with new products in oncology and urology the main drivers of the expected increase and further acquisitions seemingly on the cards. The firm has also just set up a new U.S. joint venture to pursue R&D in new therapeutic areas.
You may also be interested in...
Astellas’s overactive bladder drug mirabegron, which previously failed to pass muster in India, has now been cleared by an expert panel in the country, though competition appears to be building up alongside.
In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.